Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)Francesco Gelsomino, Andrea Ardizzoni, Ida Colantonio et al.|British Journal of Cancer|2020Cited by 25
A phase II, Open-Label, Single-Arm Trial of Carboplatin Plus Etoposide with Bevacizumab and Atezolizumab in Patients with Extended-Stage Small-Cell Lung Cancer (CeLEBrATE study): Background, Design and RationaleElisa Andrini, Andrea Ardizzoni, Giuseppe Lamberti et al.|Future Oncology|2022Cited by 7
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE studyGiuseppe Lamberti, Andrea Ardizzoni, Karim Rihawi et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 5
Phase II study of NAB-paclitaxel in sensitive and refractory relapsed SCLC (NABSTER TRIAL)Francesco Gelsomino, Andrea Ardizzoni, Marcello Tiseo et al.|Annals of Oncology|2018Cited by 2
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)Francesco Gelsomino, Andrea Ardizzoni, Marcello Tiseo et al.|British Journal of Cancer|2021Cited by 0